{"nctId":"NCT01959243","briefTitle":"Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants","startDateStruct":{"date":"2014-02-22","type":"ACTUAL"},"conditions":["Hyperemia"],"count":507,"armGroups":[{"label":"Brimonidine Tartrate","type":"EXPERIMENTAL","interventionNames":["Drug: Brimonidine Tartrate","Drug: Sodium Fluorescein","Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP"]},{"label":"Brimonidine Tartrate Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle","Drug: Sodium Fluorescein","Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP"]}],"interventions":[{"name":"Brimonidine Tartrate","otherNames":[]},{"name":"Vehicle","otherNames":[]},{"name":"Sodium Fluorescein","otherNames":[]},{"name":"Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must be at least 5 years of age at Baseline (Visit 1) of either sex and any race or ethnicity;\n* Have ocular health within normal limits, including a calculated best-corrected (if necessary) visual acuity of 0.3 logarithm of the minimum angle of resolution (logMAR) or better in each eye, as measured using an Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.\n\nExclusion Criteria:\n\n* Have any ocular/systemic health problems\n* Use of any disallowed medications during the period indicated prior to Baseline (Visit 1) and for the duration of the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"5 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"TEAE is defined as any untoward medical occurrence or undesirable event(s) that begins or worsens following administration of the study drug, whether or not considered related to the treatment by the Investigator. A TEAE is considered serious if, in the view of the Investigator or Sponsor, it results in any of the following outcomes: death, a life-threatening TEAE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, an important medical event that jeopardized the participant and required medical intervention, or sight-threatening (possibly resulting in persistent or significant loss of vision). A summary of other non-serious adverse events (AEs) and all serious AEs, regardless of causality is located in Reported AE section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Drop Comfort Assessment as Assessed by the Participant","description":"Drop comfort assessment (0-10 unit scale in which a score of 0 denotes \"very comfortable\" and 10 is \"very uncomfortable\") was performed by the participant. Participant's average score across eyes at each time point were used for analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.90"},{"groupId":"OG001","value":"0.4","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.90"},{"groupId":"OG001","value":"0.3","spread":"0.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.83"},{"groupId":"OG001","value":"0.4","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Were Fully Alert as Assessed by the Investigator on Days 1, 8, 15, and 29","description":"An alertness evaluation was performed by the Investigator asking the participant and/or participant's parent/legal guardian (pediatric participants only) a few questions based on the previous week. Using those answers, along with his/her clinical opinion, the Investigator made an assessment of the participant's level of alertness using the following 6-point scale: fully alert, alert, lethargy, obtunded, stupor, or coma.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"337","spread":null},{"groupId":"OG001","value":"170","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"336","spread":null},{"groupId":"OG001","value":"169","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"326","spread":null},{"groupId":"OG001","value":"167","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"326","spread":null},{"groupId":"OG001","value":"166","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"323","spread":null},{"groupId":"OG001","value":"164","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":337},"commonTop":["Visual Acuity Reduced","Conjunctival Hyperaemia"]}}}